Limited Uptake of Hepatitis C Treatment Among Injection Drug Users

  • Shruti H. Mehta
  • Becky L. Genberg
  • Jacquie Astemborski
  • Ravi Kavasery
  • Gregory D. Kirk
  • David Vlahov
  • Steffanie A. Strathdee
  • David L. Thomas
Original Paper


We characterized hepatitis C virus (HCV) treatment knowledge, experience and barriers in a cohort of community-based injection drug users (IDUs) in Baltimore, MD. In 2005, a questionnaire on HCV treatment knowledge, experience and barriers was administered to HCV-infected IDUs. Self-reported treatment was confirmed from medical records. Of 597 participants, 71% were male, 95% African-American, 31% HIV co-infected and 94% were infected with HCV genotype 1; 70% were aware that treatment was available, but only 22% understood that HCV could be cured. Of 418 who had heard of treatment, 86 (21%) reported an evaluation by a provider that included a discussion of treatment of whom 30 refused treatment, 20 deferred and 36 reported initiating treatment (6% overall). The most common reasons for refusal were related to treatment-related perceptions and a low perceived need of treatment. Compared to those who had discussed treatment with their provider, those who had not were more likely to be injecting drugs, less likely to have health insurance, and less knowledgeable about treatment. Low HCV treatment effectiveness was observed in this IDU population. Comprehensive integrated care strategies that incorporate education, case-management and peer support are needed to improve care and treatment of HCV-infected IDUs.


Hepatitis C virus Injection drug use Antiviral therapy Health care access 



The authors acknowledge Lisa McCall for project management, Charles Spoler for HCV counseling, Melody Schaeffer for chart abstraction, and the ALIVE study staff and participants without whom this would not have been possible. This work was supported in part by Public Health Service Grants, National Institute on Drug Abuse, DA16078, DA04334 and DA12568.


  1. 1.
    Recommendations for prevention, control of hepatitis C virus (HCV) infection and HCV-related chronic disease. (1998). Centers for disease control and prevention. Morbidity and Mortality Weekly Report, 47, 1–39.Google Scholar
  2. 2.
    Thomas, D. L., Vlahov, D., Solomon, L., et al. (1995). Correlates of hepatitis C virus infections among injection drug users. Medicine, 74, 212–220.PubMedCrossRefGoogle Scholar
  3. 3.
    Bell, J., Batey, R. G., Farrell, G. C., Crewe, E. B., Cunningham, A. L., & Byth, K. (1990). Hepatitis C virus in intravenous drug users. The Medical Journal of Australia, 153, 274–276.PubMedGoogle Scholar
  4. 4.
    van Ameijden, E. J., Van den Hoek, J. A., Mientjes, G. H., & Coutinho, R. A. (1993). A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. European Journal of Epidemiology, 9, 255–262.PubMedCrossRefGoogle Scholar
  5. 5.
    Mathei, C., Buntinx, F., & van Damme, D. P. (2002). Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: A systematic review. Journal of Viral Hepatitis, 9, 157–173.PubMedCrossRefGoogle Scholar
  6. 6.
    Manns, M. P., McHutchison, J. G., Gordon, S. C., et al. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet, 358, 958–965.PubMedCrossRefGoogle Scholar
  7. 7.
    Fried, M. W., Shiffman, M. L., Reddy, K. R., et al. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England Journal of Medicine, 347, 975–982.PubMedCrossRefGoogle Scholar
  8. 8.
    National Institutes of Health. (1997). Consensus Development Conference Panel statement: Management of hepatitis C. Hepatology, 26, 2S–10S.CrossRefGoogle Scholar
  9. 9.
    NIH (2002). Consensus statement on management of hepatitis C: 2002. NIH Consensus and State-of-the-Science Statements, 19, 1–46.Google Scholar
  10. 10.
    Sylvestre, D. L. (2005). Approaching treatment for hepatitis C virus infection in substance users. Clinical Infectious Diseases, 41(Suppl. 1), S79–S82.PubMedCrossRefGoogle Scholar
  11. 11.
    Backmund, M., Meyer, K., Von Zielonka, M., & Eichenlaub, D. (2001). Treatment of hepatitis C infection in injection drug users. Hepatology, 34, 188–193.PubMedCrossRefGoogle Scholar
  12. 12.
    Van Thiel, D. H., Anantharaju, A., & Creech, S. (2003). Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. The American Journal of Gastroenterology, 98, 2281–2288.PubMedCrossRefGoogle Scholar
  13. 13.
    Mauss, S., Berger, F., Goelz, J., Jacob, B., & Schmutz, G. (2004). A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology, 40, 120–124.PubMedCrossRefGoogle Scholar
  14. 14.
    Fleming, C. A., Craven, D. E., Thornton, D., Tumilty, S., & Nunes, D. (2003). Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: Low eligibility for interferon treatment. Clinical Infectious Diseases, 36, 97–100.PubMedCrossRefGoogle Scholar
  15. 15.
    Doab, A., Treloar, C., & Dore, G. J. (2005). Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clinical Infectious Diseases, 40(Suppl. 5), S313–S320.PubMedCrossRefGoogle Scholar
  16. 16.
    Stoove, M. A., Gifford, S. M., & Dore, G. J. (2005). The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Dependence, 77, 81–86.CrossRefGoogle Scholar
  17. 17.
    Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B. (2004). Diagnosis, management, and treatment of hepatitis C. Hepatology, 39, 1147–1171.PubMedCrossRefGoogle Scholar
  18. 18.
    Mehta, S. H., Thomas, D. L., Sulkowski, M. S., Safaein, M., Vlahov, D., & Strathdee, S. A. (2005). A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users. AIDS, 19(Suppl. 3), S179–S189.PubMedGoogle Scholar
  19. 19.
    Mehta, S. H., Lucas, G. M., Mirel, L. B., et al. (2006). Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS, 20, 2361–2369.PubMedCrossRefGoogle Scholar
  20. 20.
    Thomas, D. L., Astemborski, J., Rai, R. M., et al. (2000). The natural history of hepatitis C virus infection: Host, viral, and environmental factors. The Journal of the American Medical Association, 284, 450–456.CrossRefGoogle Scholar
  21. 21.
    Vlahov, D., Anthony, J. C., Munoz, A., et al. (1991). The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: Description of methods and characteristics of participants. NIDA Research Monograph, 109, 75–100.PubMedGoogle Scholar
  22. 22.
    Villano, S. A., Vlahov, D., Nelson, K. E., Lyles, C. M., Cohn, S., & Thomas, D. L. (1997). Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. Journal of Clinical Microbiology, 35, 3274–3277.PubMedGoogle Scholar
  23. 23.
    Mehta, S. H., Cox, A., Hoover, D. R., et al. (2002). Protection against persistence of hepatitis C. Lancet, 359, 1478–1483.PubMedCrossRefGoogle Scholar
  24. 24.
    Andersen, R. M. (1995). Revisiting the behavioral model and access to medical care: Does it matter? Journal of Health and Social Behavior, 36, 1–10.PubMedCrossRefGoogle Scholar
  25. 25.
    Taylor, L. E. (2005). Delivering care to injection drug users coinfected with HIV and hepatitis C virus. Clinical Infectious Diseases, 40(Suppl. 5), S355–S361.PubMedCrossRefGoogle Scholar
  26. 26.
    Fishbein, D. A., Lo, Y., Reinus, J. F., Gourevitch, M. N., & Klein, R. S. (2004). Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. Journal of Acquired Immune Deficiency Syndrome, 37, 1367–1375.CrossRefGoogle Scholar
  27. 27.
    Broers, B., Helbling, B., Francois, A., et al. (2005). Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. Journal of Hepatology, 42, 323–328.PubMedCrossRefGoogle Scholar
  28. 28.
    Mehta, S. H., Lucas, G. M., Mirel, L. B., et al. (2006). Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS, 20, 2361–2369.PubMedCrossRefGoogle Scholar
  29. 29.
    Restrepo, A., Johnson, T. C., Widjaja, D., et al. (2005). The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre. Journal of Viral Hepatitis, 12, 86–90.PubMedCrossRefGoogle Scholar
  30. 30.
    Davis, G. L., & Rodrigue, J. R. (2001). Treatment of chronic hepatitis C in active drug users. The New England Journal of Medicine, 345, 215–217.PubMedCrossRefGoogle Scholar
  31. 31.
    Morrill, J. A., Shrestha, M., & Grant, R. W. (2005). Barriers to the treatment of hepatitis C. Patient, provider, and system factors. Journal of General Internal Medicine, 20, 754–758.PubMedCrossRefGoogle Scholar
  32. 32.
    Matthews, G., Kronborg, I. J., & Dore, G. J. (2005). Treatment for hepatitis C virus infection among current injection drug users in Australia. Clinical Infectious Diseases, 40(Suppl. 5), S325–S329.PubMedCrossRefGoogle Scholar
  33. 33.
    Chung, R. T., Andersen, J., Volberding, P., et al. (2004). Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. The New England Journal of Medicine, 351, 451–459.PubMedCrossRefGoogle Scholar
  34. 34.
    Torriani, F. J., Rodriguez-Torres, M., Rockstroh, J. K., et al. (2004). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. The New England Journal of Medicine, 351, 438–450.PubMedCrossRefGoogle Scholar
  35. 35.
    Muir, A. J., Bornstein, J. D., & Killenberg, P. G. (2004). Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in Blacks and non-Hispanic whites. The New England Journal of Medicine, 350, 2265–2271.PubMedCrossRefGoogle Scholar
  36. 36.
    Jeffers, L. J., Cassidy, W., Howell, C. D., Hu, S., & Reddy, K. R. (2004). Peginterferon alfa-2a (40 kd) and ribavirin for Black American patients with chronic HCV genotype 1. Hepatology, 39, 1702–1708.PubMedCrossRefGoogle Scholar
  37. 37.
    Lawitz, E. J., Rodriguez-Torres, M., Muir, A., et al. (2006). 28 Days of the hepatitis C protease inhibitor VX-950 in combination with PEG-interferon-ALFA-2a and ribavirin, is well-tolerated and demonstrates robust antiviral effects. Gastroenterology, 131, 950–951.CrossRefGoogle Scholar
  38. 38.
    Strathdee, S. A., Latka, M., Campbell, J., et al. (2005). Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users. Clinical Infectious Diseases, 40(Suppl. 5), S304–S312.PubMedCrossRefGoogle Scholar
  39. 39.
    Villano, S. A., Vlahov, D., Nelson, K. E., Cohn, S., & Thomas, D. L. (1999). Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology, 29, 908–914.PubMedCrossRefGoogle Scholar
  40. 40.
    Rai, R., Wilson, L. E., Astemborski, J., et al. (2002). Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology, 35, 1247–1255.PubMedCrossRefGoogle Scholar
  41. 41.
    Imbert-Bismut, F., Ratziu, V., Pieroni, L., Charlotte, F., Benhamou, Y., & Poynard, T. (2001). Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet, 357, 1069–1075.PubMedCrossRefGoogle Scholar
  42. 42.
    Castera, L., Vergniol, J., Foucher, J., et al. (2005). Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology, 128, 343–350.PubMedCrossRefGoogle Scholar
  43. 43.
    Sylvestre, D. L., Litwin, A. H., Clements, B. J., & Gourevitch, M. N. (2005). The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. Journal of Substance Abuse Treatment, 29, 159–165.PubMedCrossRefGoogle Scholar
  44. 44.
    Kresina, T. F., Eldred, L., Bruce, R. D., & Francis, H. (2005). Integration of pharmacotherapy for opioid addiction into HIV primary care for HIV/hepatitis C virus-co-infected patients. AIDS, 19(Suppl. 3), S221–S226.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Shruti H. Mehta
    • 1
  • Becky L. Genberg
    • 1
  • Jacquie Astemborski
    • 1
  • Ravi Kavasery
    • 1
  • Gregory D. Kirk
    • 1
    • 2
  • David Vlahov
    • 3
  • Steffanie A. Strathdee
    • 4
  • David L. Thomas
    • 1
    • 2
  1. 1.Department of EpidemiologyJohns Hopkins Bloomberg School of Public HealthBaltimoreUSA
  2. 2.Division of Infectious DiseasesJohns Hopkins School of MedicineBaltimoreUSA
  3. 3.Center for Urban Epidemiologic StudiesNew York Academy of MedicineNew YorkUSA
  4. 4.Division of International Health and Cross-Cultural MedicineUniversity of California San Diego, School of MedicineSan DiegoUSA

Personalised recommendations